

CURRICULUM VITAE

Mark A. Lewis, M.D.

PRESENT TITLE AND AFFILIATION

Primary Appointment

Director, Gastrointestinal Medical Oncology, Intermountain Healthcare, Murray, Utah

CITIZENSHIP

(b) (6)

OFFICE ADDRESS

Intermountain Medical Oncology Precision Genomics Clinic
5171 S. Cottonwood St, Bldg. 1, Ste. 610, Murray, UT 84107
Phone: 801-507-3630
Fax: 801-507-3640

EDUCATION

Degree-Granting Education

Rice University, Houston, TX, BA, *summa cum laude*, 2001, Bachelor of Arts, Biology & Ancient Mediterranean Civilizations
Baylor College of Medicine, Houston, TX, MD, with High Honor, 2005, Doctor of Medicine

Postgraduate Training

Clinical Residency, Internal Medicine, Baylor College of Medicine, Houston, TX, 6/2005-6/2009
Clinical Fellowship, Hematology/Oncology, Mayo Clinic, Rochester, MN, 6/2009-6/2012

CREDENTIALS

Board Certification

American Board of Internal Medicine, Internal Medicine, 2008-2018
American Board of Internal Medicine, Hematology, 2012-2022
American Board of Internal Medicine, Medical Oncology, 2012-2022

Licensures

Active

Utah Medical License, UT Physician & Surgeon, 9903816-1205, 8/2016-9/2021
Idaho Medical License, ID Physician & Surgeon, M-14082, 2/2018-6/2021
Wyoming Medical License, WY Physician, 11633A, 8/2018-6/2020
DEA, WY, FL6554023 CS02016, 8/2018-6/2020
DEA, ID, FL7473820, 4/2018-3/2021
DEA, UT, FL6554023, 2/2017-3/2020

Inactive

Texas Medical License, TX, N0212, 6/2008-2/2018
DPS, TX, X0188302, 5/2012-2/2018
DEA, TX, FL1534622, 2/2012-3/2018
Minnesota Medical License, MN, 52281, 6/2009-6/2012

EXPERIENCE/SERVICE

Academic Appointments

Assistant Professor, Departments of General & Gastrointestinal Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 9/2012-8/2016

Administrative Appointments/Responsibilities

Section Chief, Medical Oncology, The University of Texas MD Anderson Cancer Center, Sugar Land, TX, 7/2014-8/2016
Central Region Medical Oncology Development Committee Member, Intermountain Healthcare, Murray, UT, 10/2016-10/2016-
Gastrointestinal Oncology Clinical Program Committee Member, Intermountain Healthcare, Murray, UT, 10/2016-
Oncology Clinical Trials Executive Committee Member, Intermountain Healthcare, Murray, UT, 10/2016-
Vice Chair, Institutional Review Board, Intermountain Healthcare, Murray, UT, 7/2019-

Other Appointments/Responsibilities

Co-Chair, Social Media Working Group, Southwest Oncology Group (SWOG), 5/2013-5/2015
Chair, Adolescent & Young Adult Cancer Committee, Southwest Oncology Group (SWOG), 6/2015-
Member, National Clinical Trials Network (NCTN) Adolescent & Young Adult Working Group, 6/2015-
Member, Digital Engagement Committee, Southwest Oncology Group (SWOG), 11/2015-
Member & Medical Co-Director, Huntsman-Intermountain Adolescent & Young Adult Cancer Working Group,
10/2016-
Member, ASCO TAPUR Publications Group, 2017-
Member & Patient Advocate, National Cancer Institute Neuroendocrine Task Force, 2017-
Member, National Cancer Institute Patient Advocate Steering Committee, 2017-
Member, ASCO Continuing Education Committee, 2018-
Member, Via Oncology GI Medical Oncology Pathways Committee, 2018-
Board of Directors, Neuroendocrine Tumor Research Foundation, 2019-
Co-chair, Communications Committee, North American Neuroendocrine Tumor Society, 2019-
Liaison to Board of Scientific Advisors, Neuroendocrine Tumor Research Foundation, 2020-

HONORS AND AWARDS

Baylor College of Medicine Presidential Scholarships, 2001-2005
Named Honorary Texan by Governor Rick Perry, 2002
Baylor College of Medicine High Honors for exceptional performance in the Basic Sciences, 2003
Inductee, Beta of Texas chapter of Alpha Omega Alpha, 2004
Harry & Rose Caplovitz Award for Outstanding Senior Student in Internal Medicine, 2005
L. Leighton Hill Award for Excellence in Pediatrics, 2005
Baylor College of Medicine Internal Medicine Chief Resident, 2008-2009
Henry D. McIntosh Award for Outstanding Resident in Medicine, 2008
Mayo Clinic Dr. Tow Tan Humanism in Medicine Award, 2011-2012
Mayo Clinic Dr. Edward C. Rosenow Outstanding Trainee Teaching Award, 2011-2012
Mayo Clinic Hematology/Oncology Chief Fellow, 2011-2012
Board of Directors, American Multiple Endocrine Neoplasia Support, 2012
Instructor in Medicine and Oncology, Mayo Clinic College of Medicine, 2012
Keynote speaker, The Methodist Hospital Residency & Fellowship Commencement, 2012
Recipient, Mayo Clinic Medical Oncology Small Grant for 'Analysis of Recurrence Patterns in Esophageal
Adenocarcinoma', 2012
Travel Award, International Association of Endocrine Surgeons, 2012
Dr. Mona Shimshi Memorial Lecturer, Mount Sinai School of Medicine, 2017
SWOG Leadership Academy, 2017-2019

RESEARCH

Grants and Contracts

Funded

The Hope Foundation grant for SWOG Social Media activity, 2015-2016
The Hope Foundation grant for SWOG secondary data analysis, 2017
SWOG Network Group Operations Center of the NCTN, subaward 90090627, 2017-2018
Intermountain Research Medical Foundation grant for PTCH1 analysis in pancreatic neuroendocrine tumors,
2018-2019

PUBLICATIONS

Peer-Reviewed Original Research Articles

1. Lewis MA, Agusala K, Raizen Y. Ockham's Razor is Not So Sharp. *Infectious Disease Reports* 2(2), 2010.
2. Lewis MA, Hartmann LC, Lachance DH, Jimenez RE. Opsoclonus as a suspected paraneoplastic syndrome of endometrial cancer. *Rare Tumors* 2(3):e42, 2010. e-Pub 9/2010. PMID: PMC2994525.
3. Lewis MA, Hayes TG. Talactoferrin immunotherapy in metastatic renal cell carcinoma: a case series of four long-term survivors. *J Clin Med Res* 3(1):47-51, 2/2011. PMID: PMC3194025.
4. Bernado MC, Radford JG, Menke J, Hallemeier C, Boes CJ, Lewis MA, Scheithauer B, Giannini C. Intravascular Mucinosi s: A Rare Cause of Cerebral Infarction. *Acta Neuropathologica* 121(6):785-8, 5/2011.
5. Lewis MA. Gain of function: empathy for the uncertain patient with cancer. *J Clin Oncol* 29(22):3103-4, 8/2011. e-Pub 4/2011. PMID: 21464399.

6. Lewis MA, Hendrickson AW, Moynihan TJ. Oncologic emergencies: Pathophysiology, presentation, diagnosis, and treatment. *CA Cancer J Clin.* e-Pub 8/2011. PMID: 21858793.
7. Yoon HH, Lewis MA, Shi Q, Khan M, Cassivi SD, Diasio RB, Sinicrope FA. Prognostic impact of body mass index stratified by smoking status in patients with esophageal adenocarcinoma. *J Clin Oncol* 29(34):4561-7, 12/2011. e-Pub 10/2011. PMCID: PMC3236656.
8. Lewis MA, Hubbard J. Multimodal liver-directed management of neuroendocrine hepatic metastases. *Int J Hepatol* 2011:452343, 2011. e-Pub 10/2011. PMCID: PMC3205732.
9. Lewis MA, Young WF, Thompson GB. Pre-operative Assessment of the Pancreas in Multiple Endocrine Neoplasia Type 1. *World Journal of Surgery*, 3/2012.
10. Lewis MA, Hubbard J. Treatment of Liver-Limited Disease from Colorectal Cancer. *Interventional Oncology* 2(1), 3/2012.
11. Lewis MA. A Balancing Act. *Journal of Clinical Oncology*, 4/2012.
12. Garg N, Lewis MA, Maleszewski JJ, Kalra M. Intimal sarcoma in an inflammatory aneurysm after endovascular aneurysm repair. *J Vasc Surg* 55(4):1134-7, 4/2012. e-Pub 11/2011. PMID: 22051865.
13. Yoon HH, Shi Q, Sukov WR, Lewis MA, Sattler CA, Wiktor AE, Wu TT, Diasio RB, Jenkins RB, Sinicrope FA. Adverse prognostic impact of intratumor heterogeneous HER2 gene amplification in patients with esophageal adenocarcinoma. *J Clin Oncol* 30(32):3932-8, 11/2012. e-Pub 9/2012. PMCID: PMC3675687.
14. Lewis MA, Jaramillo S, Roberts L, Fleming CJ, Rubin J, Grothey A. Hepatic artery embolization for neuroendocrine tumors: postprocedural management and complications. *Oncologist* 17(5):725-31, 2012. e-Pub 4/2012. PMCID: PMC3360912.
15. Lewis MA, Hobday TJ. Treatment of neuroendocrine tumor liver metastases. *Int J Hepatol* 2012:973946, 2012. e-Pub 11/2012. PMCID: PMC3512291.
16. Lewis MA. From victim to victor: "Breaking Bad" and the dark potential of the terminally empowered. *Cult Med Psychiatry* 37(4):656-69, 12/2013. PMID: 24136626.
17. Lewis MA, Yao JC. Molecular pathology and genetics of gastrointestinal neuroendocrine tumours. *Curr Opin Endocrinol Diabetes Obes* 21(1):22-7, 2/2014. PMID: 24310147.
18. Lewis MA, Zhao F, Jones D, Loprinzi CL, Brell J, Weiss M, Fisch MJ. Neuropathic symptoms and their risk factors in medical oncology outpatients with colorectal vs. breast, lung, or prostate cancer: results from a prospective multicenter study. *J Pain Symptom Manage* 49(6):1016-24, 6/2015. e-Pub 1/2015. PMCID: PMC4479969.
19. Lewis MA, Dicker AP. Social media and oncology: the past, present, and future of electronic communication between physician and patient. *Semin Oncol* 42(5):764-71, 10/2015. e-Pub 7/2015. PMID: 26433557.
20. Yoon HH, Lewis MA, Foster NR, Sukov WR, Khan M, Sattler CA, Wiktor AE, Wu TT, Jenkins RB, Sinicrope FA. Central nervous system relapse in patients with untreated HER2-positive esophageal or gastroesophageal junction adenocarcinoma. *Int J Cancer* 2016 Oct 1;139(7):1626-31. PMID: 27198655
21. Lewis MA. The Best Thing I Saw at ASCO. *Oncologist* 22(8): 1008-1009. Epub 2017 Jul 11.
22. Tandstad T, Kollmannsberger CK, Roth BJ, Jeldres C, Gillessen S, Fizazi K, Daneshmand S, Lowrance WT, Hanna NH, Albany C, Foster R, Cedermark GC, Feldman DR, Powles T, Lewis MA, Grimison PS, Bank D, Porter C, Albers P, De Santis M, Srinivas S, Bosl GJ, Nichols CR. Practice Makes Perfect: The Rest of the Story in Testicular Cancer as a Model Curable Neoplasm. *J Clin Oncol.* Epub 2017 Aug 30.
23. Torgeson A, Lloyd S, Boothe D, Cannon G, Garrido-Laguna I, Whisenant J, Lewis M, Kim R, Scaife C, Tao R. Chemoradiation Therapy for Unresected Extrahepatic Cholangiocarcinoma: A Propensity Score-Matched Analysis. *Ann Surg Oncol.* 2017 Oct 17.
24. Lewis MA. You and Whose Army? *The Oncologist.* 2018 November. 2018-0720. [Epub ahead of print]
25. Dizon DS, Sedrak M, Lewis MA, Cook E, Fisch MJ, Klemp JR, Sommers J, Ciccarella AM, Gralow JR, Lawton W, Nichols CR. Incorporating digital tools to improve clinical trial infrastructure: a white paper from the digital engagement committee of SWOG. *JCO Clinical Cancer Informatics.* 2018 Dec; 2:1-8
26. Swords DS, Skarda DE, Sause WT, Gawlick U, Cannon GM, Lewis MA, Scaife CL, Gygi JA, Tae Kim H. Surgeon-Level Variation in Utilization of Local Staging and Neoadjuvant Therapy for Stage II-III Rectal Adenocarcinoma. *J Gastrointest Surg.* 2019 Apr;23(4):659-66.
27. Holowatyj AN, Lewis MA, Pannier ST, Kirchoff AC, Hardikar S, Figueiredo JC, Huang LC, Shibata D, Schmit SL, Ulrich CM. Clinicopathologic and Racial/Ethnic Differences of Colorectal Cancer Among Adolescents and Young Adults. *Clin Transl Gastroenterol.* 2019 Jul;10(7):e00059.
28. Holowatyj AN, Ulrich CM, Lewis MA. Racial/ethnic patterns of young-onset noncardia gastric cancer. *Cancer Prev Res (Phila).* 2019 Aug 16.
29. Kaddas HK, Pannier ST, Mann K, Waters AR, Salmon S, Tsukamoto T, Warner EL, Fowler B, Lewis MA, Fair DB, Kirchoff AC. Age-Related Differences in Financial Toxicity and Unmet Resource Needs Among Adolescent and Young Adult Cancer Patients. *J Adolesc Young Adult Oncol.* 2019 Sep 16.

30. Pieterman CRC, Sadowski SM, Maxwell JE, Katz MHG, Lines KE, Heaphy CM, Tirosh A, Blau JE, Perrier N, Lewis MA, Metzcar JP, Halperin DM, Thakker RV, Valk GD. MEN1-related PanNETs: identifying unmet clinical needs and future directives. *Endocr Relat Cancer*. 2020 Feb 1.
31. Roth ME, Unger JM, O'Mara AM, Lewis MA, Budd T, Johnson RH, Pollock BH, Blanke C, Freyer DR. Enrollment of adolescents and young adults onto SWOG cancer research network clinical trials: A comparative analysis by treatment site and era. *Cancer Med*. 2020 Mar;9(6):2146-2152.
32. Lewis MA. Between Scylla and Charybdis - Oncologic Decision Making in the Time of Covid-19. *N Engl J Med*. 2020 Apr 7.
33. Lewis MA. Hereditary Syndromes in Neuroendocrine Tumors. *Curr Treat Options Oncol*. 2020;21(6):50. 2020 Apr 30.
34. Pieterman CRC, Sadowski SM, Maxwell JE, Katz MHG, Lines KE, Heaphy CM, Tirosh A, Blau JE, Perrier N, Lewis MA, Metzcar JP, Halperin DM, Thakker RV, Valk GD. MEN1-related PanNETs: identifying unmet clinical needs and future directives [published online ahead of print, 2020 Feb 1]. *Endocr Relat Cancer*.
35. Kuderer NM et al; COVID-19 and Cancer Consortium. Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study. *Lancet*. 2020 Jun 20;395(10241):1907-1918.
36. Holowatyj AN, Viskochil R, Ose D, Tingey B, Haaland B, Wilson D, Larson M, Feltz S, Lewis MA, Colman H, Ulrich CM. Diabetes, Body Fatness, and Insulin Prescription Among Adolescents and Young Adults with Cancer. *J Adolesc Young Adult Oncol*. 2020 Jul 29
37. Lewis MA. Disunited State of Cancer Care in America. *JCO Oncol Pract*. 2020 Sep 24.
38. Rivera DR et al; COVID-19 and Cancer Consortium. Utilization of COVID-19 Treatments and Clinical Outcomes among Patients with Cancer: A COVID-19 and Cancer Consortium (CCC19) Cohort Study. *Cancer Discov*. 2020 Oct;10(10):1514-1527.
39. The COVID-19 and Cancer Consortium. A Systematic Framework to Rapidly Obtain Data on Patients with Cancer and COVID-19: CCC19 Governance, Protocol, and Quality Assurance. *Cancer Cell*. E-pub 2020 Oct.

Abstracts

1. Lewis MA, Shi Q, Khan M, Cassivi SD, Diasio RB, Sinicrope F, Yoon HH. Association of body mass index (BMI) with smoking and prognosis in 721 patients with esophagogastric adenocarcinoma. *J Clin Oncol* 29(suppl; abstr e14635), 5/2011.
2. Jaramillo S, Lewis MA, Roberts LR, Rubin J, Grothey A. Hospitalization after hepatic artery embolization (HAE) for neuroendocrine tumors (NET) 2011 ASCO Annual Meeting. *J Clin Oncol* 29(suppl; abstr e 14553), 6/2011.
3. Lewis M, Young WF, Thompson GB. Preoperative assessment of the MEN 1 pancreas. *World Journal of Surgery* (#suppl 1; abstr 0895), 2011.
4. Lewis MA, Yoon HH, Shi Q, Diasio RB, Sinicrope FA. Post-recurrence survival in patients with previously resected esophageal adenocarcinoma (EAC). *J Clin Oncol* 30(suppl; abstr 4075), 5/2012.
5. Lewis MA, Yao JC. Bronchial neuroendocrine neoplasms: a surveillance epidemiology and end results (SEER) database review of demographics and survival in 187,991 cases. *J Clin Oncol* 33(suppl; abstr 4097), 5/2015.
6. Lewis MA, Yao JC. Bronchial neuroendocrine neoplasms: a surveillance epidemiology and end results (SEER) database review of treatment outcomes. *J Clin Oncol* 33(suppl; abstr 4098), 5/2015.
7. Ravi P, Lewis MA, Kourelis T, Ansell S, Costello B, Quevedo F, Kohli M, Dronca R, Bryce A, Litzow M, Pagliaro L, Patnaik MM. Inability to complete the second of planned tandem autologous stem cell transplantations for metastatic germ cell tumors: reasons, toxicity and impact on outcomes. 2017 ASH Annual Meeting.
8. Lewis MA, Haslem DS, Thota R, Rhodes TD, Barker T, Moulton B, Abraham T, Fulde G, Romero R, Christensen B, Nadauld L. Mutational landscape of metastatic colorectal cancer: Aggregate insights from a molecular tumor board. 2018 ASCO Gastrointestinal Cancers Symposium.
9. Thota R, Lewis MA, Raghunath S, Haslem DS, Nadauld L, Rhodes TD, Moulton B, Abraham T, Romero R, Fulde G, Christensen B, Barker T. Utility of next-generation sequencing in clinical decision making in hepatocellular carcinoma (HCC). 2018 ASCO Gastrointestinal Cancers Symposium.
10. Thota R, Lewis MA, Nadauld L, Haslem DS, Rhodes TD, Christensen B, Fulde, G, Abraham T, Romero R, Moulton B, Raghunath S, Barker T. Cell cycle checkpoint defects in gastrointestinal malignancies. 2018 ASCO Gastrointestinal Cancers Symposium.
11. Thota R, Fulde G, Lewis MA, Haslem DS, Rhodes TD, Nadauld L, Moulton B, Romero R, Abraham T, Christensen B, Raghunath S, Barker T. DNA damage repair (DDR) pathway defects in gastrointestinal (GI) malignancies. 2018 ASCO Gastrointestinal Cancers Symposium.
12. Thota R, Christensen B, Fulde G, Lewis MA, Haslem DS, Rhodes TD, Nadauld L, Barker T. Characterization of the tumor mutation burden in hepatobiliary tumors. 2019 ASCO Gastrointestinal Cancers Symposium.

Book Chapters

1. Lewis MA, Yoon HH. Systemic therapy and targeted agents in advanced esophageal cancer. Esophageal Cancer and Barrett's Esophagus, 3rd ed. 251-264. Blackwell Publishing. 12/15.
2. Lewis MA, Hogan WJ, Moynihan TJ. Oncologic Emergencies. American Cancer Society's Oncology in Practice: Clinical Management. In press. Wiley Publishing.

EDITORIAL AND REVIEW ACTIVITIES

Journal Reviewer

Digital Health
Journal of Clinical Oncology
JCO Precision Oncology
JCO Clinical Cancer Informatics

Other Media

ASCO Self-Evaluation Program (SEP), 2012-annually to present
Social Media Editor, Cancer Knowledge Network, 2015-2016

TEACHING

Formal Teaching

MD Anderson Hematology/Oncology Board Review, 9/2015
MD Anderson Hematology/Oncology Board Review, 9/2016
MD Anderson Hematology/Oncology Board Review, 9/2018
MD Anderson Hematology/Oncology Board Review, 9/2019

Supervisory Teaching

High school observership, Clements High School, (b) (6), 2015
High school observership, Katy High School, (b) (6), 2016
College student observership, Appalachian State University, (b) (6), 2015

CONFERENCES AND SYMPOSIA

Organization of Conferences/Symposia (Include chairing session)

SWOG, Social Media Working Group, San Francisco, CA, Co-Chair, 5/2013
Vanderbilt University, Multiple Endocrine Neoplasia Seminar, Nashville, TN, Organizer/Speaker, 9/2013
SWOG, Social Media Working Group, Chicago, IL, Co-Chair, 10/2013
6th International Scientific Conference Cancer Forum, Discussant, Dammam, Saudi Arabia, Co-Chair, 4/2014
SWOG, Social Media Working Group, San Francisco, CA, Co-Chair, 5/2014
SWOG, Social Media Working Group, Chicago, IL, Co-Chair, 10/2014
SWOG, Social Media Working Group, San Francisco, CA, Co-Chair, 5/2015
SWOG, Social Media Working Group, Chicago, IL, Co-Chair, 10/2015
SWOG, Adolescent & Young Adult Committee, Chicago, IL, Chair, 10/2015
SWOG, Adolescent & Young Adult Committee, San Francisco, CA, Chair, 4/2016
SWOG, Adolescent & Young Adult Committee, Chicago, IL, Chair, 9/2016
Vanderbilt University, Multiple Endocrine Neoplasia Seminar, Nashville, TN, Speaker, 2/2017
SWOG, Adolescent & Young Adult Committee, San Francisco, CA, Chair, 4/2017
SWOG, Adolescent & Young Adult Committee, Chicago, IL, Chair, 10/2017
SWOG, Adolescent & Young Adult Committee, San Francisco, CA, Chair, 4/2018
SWOG, Adolescent & Young Adult Committee, Chicago, IL, Chair, 10/2018
SWOG, Adolescent & Young Adult Committee, San Francisco, CA Chair, 4/2019
SWOG, Adolescent & Young Adult Committee, Chicago, IL, Chair, 10/2019
SWOG, Adolescent & Young Adult Committee, Chicago, IL, Chair, 9/2020

Presentations at State, National or International Conferences

Invited

A Balancing Act, Michigan Society of Hematology/Oncology Fellows' Forum, Plymouth, MI, 2013.
The youngest-ever malignancy associated with multiple endocrine neoplasia type 1 (MEN 1). 14th
International Workshop on Multiple Endocrine Neoplasia, Vienna, Austria, 2014.
Adolescent & Young Adult research. Critical Mass conference, Chicago, IL, 2015.
Online polling is a tool for preliminary assessment of post-operative quality of life in MEN1-directed surgeries.
15th International Workshop on Multiple Endocrine Neoplasia, Utrecht, the Netherlands, 2016.
How Health IT Is Driving Clinical Value In Precision Medicine Cancer Care. HIMSS. Orlando, FL, 2017.

Body Mass Index In Relation to AYA Oncology Outcomes. COG meeting, St Louis, MI, 2017.
Shared Decision-Making in Metastatic Colorectal Cancer. HIMSS. Las Vegas, NV, 2018.
North American Neuroendocrine Tumor Society (NANETS) Regional Seminar, Salt Lake City, UT, 2018.
Financial Toxicity of AYA Cancer Patients by Age of Diagnosis. 3rd Global AYA Congress, Sydney, Australia, 2018.
Analysis of Accrual Patterns of AYA Patients to a National Cooperative Research Group Over 25 Years: The SWOG Experience. 3rd Global AYA Congress, Sydney, Australia, 2018.
Pancreatic Tumors in MEN 1. Multiple Endocrine Neoplasia Syndromes Symposium, University of North Carolina, Chapel Hill, NC, 2019.
Early-Onset Colorectal Cancer: A Biologically Distinct Threat? Great Debates In Gastrointestinal Malignancies, Chicago, IL, 2019.
The Second Coming of the Gutenberg Press: Digital Dissemination of Information to Patients and Physicians. SWOG Plenary Session, Chicago, IL, 2019.
Lost in the Woods: Seeking Novel Therapies from a Patient's Perspective. Drug Development for Rare Mutations Clinical Science Symposium, ASCO Virtual Scientific Program, 2020.

Other, Including Scientific Exhibitions

Storan E, Lewis MA, Al-Kali A. Cutaneous Vasculitis Associated with All-Trans Retinoic Acid (ATRA) Therapy for Acute Promyelocytic Leukemia, 2012 European Academy of Dermatology and Venereology Annual Meeting, 2012
Lewis MA, Yoon HH, Shi Q, Diasio RB, Sinicrope FA. Post-recurrence survival in patients with previously resected esophageal adenocarcinoma (EAC), 2012 American Society of Clinical Oncology (ASCO) Annual Meeting, Chicago, IL, 2012
Lewis MA, Yao JC. Bronchial neuroendocrine neoplasms: A Surveillance Epidemiology and End Results (SEER) database review of demographics and survival in 187,991 cases, 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Chicago, IL, 2015
Lewis MA, Yao JC. Bronchial neuroendocrine neoplasms: A Surveillance Epidemiology and End Results (SEER) database review of treatment outcomes, 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Chicago, IL, 2015
"The Fortune and Folly of Self-Diagnosis," Multidisciplinary Parathyroid Neoplasia Conference, MD Anderson Cancer Center, 4/2016
"A Case Study in Identifying a Familial Tumor Syndrome," HSHS St. Vincent Hospital Oncology Rounds, Green Bay, Wisconsin, 10/2016

Seminar Invitations from Other Institutions

Social Media in Oncology, Boehringer Ingelheim, Vienna, Austria, 6/2015
Health Stakeholders Event, Facebook, Menlo Park, CA, 1/2019

Lectureships and Visiting Professorships

Baylor College of Medicine Internal Medicine Grand Rounds, "The Fortune and Folly of Self-Diagnosis", Houston, TX, 11/2015
Henry Ford Cancer Institute Grand Rounds, "The Fortune and Folly of Self-Diagnosis", Detroit, MI, 8/2108
Huntsman Cancer Institute Fellows' Rounds, "The Fortune and Folly of Self-Diagnosis", Salt Lake City, UT, 1/2019
Huntsman Cancer Institute Fellows' Rounds, "The Fortune and Folly of Self-Diagnosis", Salt Lake City, UT, 5/2020

Other Presentations at State and Local Conferences

Finalist in oral presentation. Talactoferrin as a novel therapeutic agent in metastatic renal cell carcinoma, 2007 Texas Society of Medical Oncology Meeting, Houston, TX, 2007
Oral talactoferrin (recombinant human lactoferrin) as a novel therapeutic agent in metastatic renal cell carcinoma, 2nd place in Clinical Research at 2008 Baylor College of Medicine Housestaff Research Symposium, Baylor College of Medicine, Houston, TX, 2008
Neuropathic Symptoms and their Risk Factors in Medical Oncology Outpatients with Colorectal versus Breast, Lung or Prostate Cancer - Results from a Prospective Multicenter Study, 2014 Cancer Survivorship Research Symposium, MD Anderson Cancer Center, Houston, TX, 2014

PROFESSIONAL MEMBERSHIPS/ACTIVITIES

Professional Society Activities, with Offices Held

National and International

American Multiple Endocrine Neoplasia Support

Vice President, 2012 to present

American Society of Clinical Oncology

Member, 2012 to present

SWOG

Member, 2012 to present

North American Neuroendocrine Tumor Society

Member, Communications Committee, 2017 to present

Neuroendocrine Tumor Research Foundation

Member, Board of Directors, 2018 to present